Eli Lilly shares data from two phase 3 tirzepatide studies

Betsy Goodfellow | July 28, 2023 | News story | Research and Development Eli Lilly, Obesity, clinical trial, tirzepatide, weight loss 

Eli Lilly has announced results from its two phase 3 tirezepatide studies in adult patients with obesity or who are overweight with weight-related comorbidities, excluding type 2 diabetes.

SURMOUNT-3 and SURMOUNT-4 met all primary and key secondary objectives for tirzepatide when compared to a placebo dose. Participants of both trials on the drug who followed intensive lifestyle intervention or who continued tirzepatide treatment, achieved up to 26.6% mean weight loss.

The overall safety profile remained consistent with previously reported SURMOUNT and SURPASS trials and to similar therapies already approved for the treatment of obesity. The most commonly reported adverse events were gastrointestinal-related and were mainly mild to moderate in severity.

Jeff Emmick, MD PhD, senior vice president of product development at Eli Lilly, commented: “The results of SURMOUNT-3 and -4 showed the highest level of weight loss observed in the SURMOUNT programme to date. Whether taking tirzepatide for 88 weeks in SURMOUNT-4 or taking tirzepatide for 72 weeks following intensive caloric restriction in SURMOUNT-3, participants achieved similar mean weight reduction — about 26%. The findings from SURMOUNT-3 challenge the notion that patients living with obesity or overweight can achieve their weight loss goals with diet and exercise alone. Additionally, the findings from SURMOUNT-4 reinforce that obesity should be regarded like other chronic diseases where chronic therapy may be needed to maintain treatment benefits.” Betsy Goodfellow

Related Content

Nuvectis Pharma initiates phase 1a NXP900 clinical trial

Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …


Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults

Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human …

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase …

Latest content